Panagiotis J Vlachostergios: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

• The congress is free to attend.
• Register via the link.

Co-Chair of VIRO

Images

Name

Rana McKay Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on  “Future Directions: Emerging Agents and Combinations.” She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Panagiotis J Vlachostergios

Dr. Panagiotis J Vlachostergios is an Assistant Professor of Clinical Medicine at Weill Cornell Medical College, New York, and Consultant Medical Oncologist at the IASO Thessalias Medical Center, Greece.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Panagiotis J Vlachostergios will present on “Biomarkers for Adjuvant Therapy Benefit in Renal Cell Carcinoma.” His presentation will explore:

• The evolving landscape of adjuvant therapy in RCC, highlighting successes such as immune checkpoint inhibitor pembrolizumab in high-risk patients.
• The critical need for biomarkers to identify patients most likely to benefit from adjuvant treatments while minimizing overtreatment.
• Promising biomarker approaches including transcriptomic signatures, liquid biopsies (ctDNA), and molecular imaging that improve patient selection and outcome prediction.
• The challenges of tumor heterogeneity and toxicity risk in the adjuvant setting and how biomarker-guided strategies can optimize personalized treatment.

Dr. Vlachostergios emphasizes the importance of integrating innovative biomarker research into clinical practice to enhance the effectiveness and safety of adjuvant therapies in RCC.

Global Voices in Renal Oncology (VIRO) 2025